Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Pharm Bioallied Sci ; 15(Suppl 2): S987-S989, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37693956

ABSTRACT

Objective: The purpose of this research was to examine patients' periodontal health before, during, and after treatment using a fixed orthodontic device. Methods: Forty normal teenagers with full sets of permanent teeth and a clinical need for fixed orthodontics participated. Individuals were chosen from the Class I population who would benefit from utilizing traditional orthodontic braces and techniques that did not need extractions. Respondents were sent to the periodontist for required checkups after the placement of a fixed orthodontic device at 3-, 6-, 12-, and 24-month intervals, respectively, till the conclusion of orthodontic treatment. Results: After having a fixed orthodontic device put in place, patients had a rise in the average values of the Plaque Index and Sulcus Bleeding Index at each checkup. Keeping an eye on the progression three months, six months, a year, and two years after the initiation of orthodontic treatment reveals a statistically significant difference in the presence of gingival hyperplasia. Conclusion: Patients' periodontal health before, during, and after fixed orthodontic treatment shows the need for close collaboration between the orthodontist and the periodontist.

2.
J Pharm Bioallied Sci ; 15(Suppl 2): S993-S996, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37694007

ABSTRACT

Background: Minimally invasive dentistry (MID) includes caries detection using caries risk assessment (CRA), early localization of nascent carious sores including necessary and voluntary avoidance, and remineralization of demineralized veneer and dentin when diagnosed early for these reasons. Although the dentistry curriculum prioritizes the benefits of MID in tooth protection, this research is seldom included in classroom instruction. Aim: The purpose of this research was to gauge the level of understanding that dental professionals have about MID ideas. Methods: An online questionnaire measuring MID knowledge and application was used to compile the data. The Chi-square tests were run for statistical analysis in the Statistical Package for the Social Sciences (SPSS). Results: Just 42.2% of the dentists who replied had MID training during their undergraduate or internship years, and the majority of that training came via lectures (45.2%). The majority (almost 81%) of respondents believed that CRA should be performed on all patients. Differences in knowledge and experience with atraumatic restorative therapy and the sandwich approach for treating caries in permanent teeth and high caries risk children were shown to be statistically significant (P 0.05). Conclusion: Dentists know about the benefits of MID, but their patients are not reaping those benefits since so many dentists still use the old methods of treating complete caries.

3.
Int J Heart Fail ; 5(3): 159-168, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37554694

ABSTRACT

Background and Objectives: Readmissions in heart failure (HF), historically reported as 20%, contribute to significant patient morbidity and high financial cost to the healthcare system. The changing population landscape and risk factor dynamics mandate periodic epidemiologic reassessment of HF readmissions. Methods: National Readmission Database (NRD, 2019) was used to identify HF-related hospitalizations and evaluated for demographic, admission characteristics, and comorbidity differences between patients readmitted vs. those not readmitted at 30-days. Causes of readmission and predictors of all-cause, HF-specific, and non-HF-related readmissions were analyzed. Results: Of 48,971 HF patients, the readmitted cohort was younger (mean 67.4 vs. 68.9 years, p≤0.001), had higher proportion of males (56.3% vs. 53.7%), lowest income quartiles (33.3% vs. 28.9%), Charlson comorbidity index (CCI) ≥3 (61.7% vs. 52.8%), resource utilization including large bed-size hospitalizations, Medicaid enrollees, mean length of stay (6.2 vs. 5.4 days), and disposition to other facilities (23.9% vs. 20%) than non-readmitted. Readmission (30-day) rate was 21.2% (10,370) with cardiovascular causes in 50.3% (HF being the most common: 39%), and non-cardiac in 49.7%. Independent predictors for readmission were male sex, lower socioeconomic status, nonelective admissions, atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, anemia, and CCI ≥3. HF-specific readmissions were significantly associated with prior coronary artery disease and Medicaid enrollment. Conclusions: Our analysis revealed cardiac and noncardiac causes of readmission were equally common for 30-day readmissions in HF patients with HF itself being the most common etiology highlighting the importance of addressing the comorbidities, both cardiac and non-cardiac, to mitigate the risk of readmission.

4.
Int J Cardiol Heart Vasc ; 40: 101008, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35330979

ABSTRACT

Background: Though the co-prevalence of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized, the role of transcatheter aortic valve replacement (TAVR) in patients with CA remains unclear. Methods: The National Readmission Dataset (2016-18) and ICD-10 codes were used to identify those with CA and AS, in conjunction with TAVR status. The primary outcome was a composite of heart failure (HF) readmissions and all-cause mortality. All outcomes were followed up to 1-year with a median follow up time 172-days. Kaplan-Meier curves and multivariate cox-proportional hazard regression were used for time-to-event analysis. Results: Of 1,127 CA patients, 92 (8.2%) had undergone TAVR. Patients with CA who received TAVR were younger and more commonly had coronary artery disease (67.3% vs 44.2%). Teaching (93.6% vs 81.1%) and large hospitals (77.7% vs 59.3%) performed more TAVRs. In multivariate analysis, TAVR was associated with an improved primary outcome (8.9% vs 24.4%, HR:0.32; 95% CI 0.14-0.71, p = 0.007) and with reduced HF readmissions (3.8% vs 19.4%, HR:0.22; 95% CI 0.07-0.68, p = 0.008). All-cause mortality was numerically lower in TAVR patients with CA but did not reach statistical significance. Conclusions: CA patients who receive TAVR are younger, and the procedure is more commonly performed at large, teaching hospitals. TAVR was associated with a lower primary composite outcome of HF readmissions and all-cause mortality.

5.
Heart Rhythm O2 ; 2(1): 53-63, 2021 Feb.
Article in English | MEDLINE | ID: mdl-34113905

ABSTRACT

BACKGROUND: No studies assessed impact of atrial flutter (AFL) ablation on outcomes in patients with AFL and concurrent heart failure (HF). OBJECTIVES: To assess the effect of AFL ablation on mortality and HF readmissions in patients with AFL and HF. METHODS: This retrospective cohort study identified 15,952 patients with AFL and HF from the 2016-17 Nationwide Readmissions Database. The primary outcome was a composite of all-cause mortality and/or HF readmission at 1 year. Secondary outcomes included HF readmission, all-cause mortality, and atrial fibrillation (AF) readmission at 1 year. Propensity score match (1:2) algorithm was used to adjust for confounders. Cox proportional hazard regression was used to generate hazard ratios. RESULTS: Of the 15,952 patients, 9889 had heart failure with reduced ejection fraction (HFrEF) and 6063 had heart failure with preserved ejection fraction (HFpEF). In the matched HFrEF cohort (n = 5421), the primary outcome was significantly lower in patients undergoing ablation (HR 0.72, 95% CI 0.61-0.85, P < .001). HF readmission (HR 0.73, 95% CI 0.61-0.89, P = .001), all-cause mortality (HR 0.62, 95% CI 0.46-0.85, P = .003), and AF readmission (HR 0.63, 95% CI 0.48-0.82, P = .001) were also significantly reduced. In the matched HFpEF cohort (n = 2439), the primary outcome was lower in the group receiving ablation but was not statistically significant (HR 0.80, 95% CI 0.63-1.01, P = .065). CONCLUSION: In patients with AFL and HFrEF, AFL ablation was associated with lower mortality and HF readmissions at 1 year. Patients with AFL and HFpEF did not show a similar significant reduction in the primary outcome.

6.
JACC Cardiovasc Interv ; 14(6): 623-636, 2021 03 22.
Article in English | MEDLINE | ID: mdl-33736770

ABSTRACT

OBJECTIVES: The aim of this study was to determine the impact of invasive approaches and revascularization in patients with cocaine-associated non-ST-segment elevation myocardial infarction (NSTEMI). BACKGROUND: The role of invasive approaches in cocaine-associated NSTEMI is uncertain. METHODS: This retrospective cohort study identified 3,735 patients with NSTEMI and history of cocaine use from the Nationwide Readmissions Database from 2016 to 2017. Invasive approaches were defined as coronary angiography, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). Revascularization was defined as PCI and CABG. The primary efficacy outcome was major adverse cardiac events (MACE), and the primary safety outcome was emergent revascularization. Nonadherence was identified using appropriate International Classification of Diseases-Tenth Revision codes. Two propensity-matched cohorts were generated (noninvasive vs. invasive and noninvasive vs. revascularization) through multivariate logistic regression. RESULTS: In the propensity score-matched cohorts, an invasive approach (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.56 to 0.92; p = 0.008) and revascularization (HR: 0.54; 95% CI: 0.40 to 0.73; p < 0.001) (compared with a noninvasive approach) were associated with a lower rate of MACE, without an increase in emergent revascularization. On stratification, PCI and CABG individually were associated with a lower rate of MACE. Emergent revascularization was increased with PCI (HR: 1.78; 95% CI: 1.12 to 2.81; p = 0.014) but not with CABG. Nonadherent patients after PCI and CABG did not have significant difference in rate of MACE. PCI in nonadherent patients was associated with an increase in emergent revascularization (HR: 4.45; 95% CI: 2.07 to 9.57; p < 0.001). CONCLUSIONS: Invasive approaches and revascularization for cocaine-associated NSTEMI are associated with lower morbidity. A history of medical nonadherence was not associated with a difference in morbidity but was associated with an increased risk for emergent revascularization with PCI.


Subject(s)
Cocaine , Coronary Artery Disease , Non-ST Elevated Myocardial Infarction , Percutaneous Coronary Intervention , Cocaine/adverse effects , Humans , Non-ST Elevated Myocardial Infarction/diagnostic imaging , Non-ST Elevated Myocardial Infarction/therapy , Percutaneous Coronary Intervention/adverse effects , Retrospective Studies , Treatment Outcome
7.
Catheter Cardiovasc Interv ; 98(1): E153-E162, 2021 07 01.
Article in English | MEDLINE | ID: mdl-33166062

ABSTRACT

BACKGROUND: Transcatheter aortic valve replacement (TAVR) can be an effective option for high-risk Aortic Regurgitation (AR) patients. Although international experiences of TAVR for AR are published, U.S. data are limited. This study sought to report the short-term outcomes of TAVR in AR in the U.S. METHODS: Study cohorts were derived from the Nationwide Inpatient Sample (NIS) and Nationwide Readmissions Database (NRD) 2016-17. TAVR and AR were identified using ICD-10-CM-codes. The key outcomes were all-cause mortality, disabling stroke, valvular complications, complete heart block (CHB)/permanent pacemaker placement (PPM), open-heart surgery, acute kidney injury (AKI) requiring dialysis, and vascular complications. Multivariate logistic regression was used to adjust for confounders. RESULTS: 915 patients from the NIS (male-71%, age ≥65-84.2%) and 822 patients from the NRD (male-69.3%, age ≥65-80.5%) underwent TAVR for AR. The median length of stay (LOS) was 4 days for both cohorts. In-hospital mortality was 2.7%, and 30-day mortality was 3.3%. Disabling strokes were noted in 0.6% peri-procedurally and 1.8% at 30-days. Valve-related complications were 18-19% with paravalvular leak (4-7%) being the most common. Approximately 11% of patients developed CHB and/or needed PPM in both cohorts. In NRD, 2.2% of patients required dialysis for AKI, 1.5% developed vascular complications, and 0.6% required open-heart surgery within 30-days post-procedure. Anemia was predictive of increased overall complications and valvular complications, whereas peripheral vascular disease was a predictor of increased valvular complications and CHB/PPM. CONCLUSION: TAVR is a promising option in AR. Further studies are necessary for the expansion of TAVR as the standard treatment in AR.


Subject(s)
Aortic Valve Insufficiency , Aortic Valve Stenosis , Transcatheter Aortic Valve Replacement , Aged , Aortic Valve/diagnostic imaging , Aortic Valve/surgery , Aortic Valve Insufficiency/diagnostic imaging , Aortic Valve Insufficiency/etiology , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/surgery , Female , Hospital Mortality , Humans , Male , Postoperative Complications/etiology , Risk Factors , Time Factors , Transcatheter Aortic Valve Replacement/adverse effects , Treatment Outcome
8.
Am J Cardiol ; 137: 45-54, 2020 12 15.
Article in English | MEDLINE | ID: mdl-33002464

ABSTRACT

Due to limited real-world data, the aim of this study was to explore the impact of catheter ablation (CA) for atrial fibrillation (AF) in heart failure (HF). This retrospective cohort study identified 119,694 patients with AF and HF from the Nationwide Readmissions Database (NRD) from 2016 to 2017. Propensity-matching was generated using demographics, comorbidities, hospital and other characteristics through multivariate logistic regression. Greedy's propensity score match (1:15) algorithm was used to create matched data. The primary end point was a composite of HF readmission and mortality at 1 year. Secondary outcomes include HF readmission, mortality, AF readmission, and any-cause readmission at 1 year. Of the 119,694 patients, 63,299 had HF with reduced ejection fraction (HFrEF), and 56,395 had HF with preserved ejection fraction (HFpEF). In the overall HFrEF cohort, the primary outcome was similar (HR, 95% confidence interval, p-value) (1.01, 0.91 to 1.13, 0.811). AF readmission (0.41, 0.33 to 0.49, <0.001) and any readmission (0.87, 0.82 to 0.93, <0.001) were reduced with CA. In the propensity-matched HFrEF cohort, results were unchanged (primary outcome: 1.10, 0.95 to 1.27, 0.189; AF readmission: 0.46, 0.36 to 0.59, <0.001; any readmission: 0.89, 0.82 to 0.98, 0.015). In the overall HFpEF cohort, the primary outcome was similar (0.90, 0.78 to 1.04, 0.154). AF readmission was reduced with CA (0.54, 0.44 to 0.65, <0.001). In the propensity-matched HFpEF cohort, results were unchanged (primary outcome 1.10, 0.92 to 1.31, 0.289; AF readmission 0.44, 0.33 to 0.57, <0.001). CA did not reduce mortality and HF readmission at one year irrespective of the type of HF, but significantly reduce readmission due to AF.


Subject(s)
Atrial Fibrillation/surgery , Catheter Ablation/methods , Heart Failure/epidemiology , Stroke Volume/physiology , Adolescent , Adult , Aged , Atrial Fibrillation/epidemiology , Atrial Fibrillation/physiopathology , Comorbidity , Female , Heart Failure/physiopathology , Humans , Male , Middle Aged , Recurrence , Retrospective Studies , Risk Factors , Survival Rate/trends , United States/epidemiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...